The Executive and Management Team
Parsin Haji Reza: PhD, Co-founder and Chairman of the Board
Parsin is an Assistant Professor at the University of Waterloo with more than 10 years experience in optics and biomedical engineering. Parsin has discovered the PARS effect and co-founded illumiSonics in November 2014. He was the CEO of illumiSonics until March 2018. Currently, he chairs the illumiSonics board and oversees the direction and vision for illumiSonics. Parsin has published more than 22 peer reviewed papers in optics and biomedical Engineering. He has received several international and national awards and scholarships for his scientific and entrepreneurial achievements.
Michael Weickert : PhD, CEO
Michael has been an executive in devices and biotech for over 26 years, as CEO of Pacylex, Sonescence and SEA Medical Systems, CBO of Strategent Life Sciences, Corium, and Therashock, VP of development at SciDose and Auspex, and Senior Program Executive or Manager at Nektar and Ligand. Key roles included raising capital, establishing and maintaining business partnerships, building teams, and developing new products. He raised Seed through Series C capital and established strategic partnerships worth more than $175 Million. Dr. Weickert received his Ph.D. in Genetics from the University of Wisconsin and worked at the National Cancer Institute of NIH. He holds 7 issued and 19 pending patents and has 23 publications.
John Mackey: MD., Board Member
John is a medical oncologist and Director, Clinical Trials Unit at the Cross Cancer Institute, and Professor of Oncology, University of Alberta. He is a founder of three companies in the medtech / biotech space, and is Executive Director of Translational Research In Oncology (TRIO), a global clinical trial company with its head office in Edmonton. He directs the clinical development and evaluation of Illumisonics technology.
Bruce Johnson: B.Sc. Board Member
Bruce has been the Chief Executive of a number of companies primarily in the technology sector. He was the co-founder and CEO of Intuit Canada and UK and grew that organization to 700 staff and revenues of around $115M. He currently is active in coaching entrepreneurs and sits on a number of boards including Campbell Scientific Canada, HeadCount Corporation, Visio Media Inc., Social Asset Management Inc., Rehabtronics Inc., and the Alberta Machine Intelligence Institute.
Deepak Dinakaran, MD., Medical Director
Deepak is a Radiation Oncology resident completing his PhD in Experimental Oncology at the University of Alberta. He received his MD from McGill University in 2014, and H.BSc from University of Toronto in 2010. His clinical interests include CNS and genitourinary cancers with a focus on modern radiotherapy techniques including stereotactic body radiotherapy and brachytherapy. He researches radiation-activated theranostic nanoparticles, radiomics, predictive biomarkers, pharmacotherapies, and conducts clinical trials.
Kevan Bell, B.Sc., Engineering Director
Kevan is completing his PhD in biomedical engineering at the University of Alberta with heavy focus on optical imaging devices and optical physics. He has received multiple provincial and national awards and scholarships. Much of his research has revolved around the development of novel biomedical imaging technologies including photoacoustic remote sensing (PARS) microscopy, one of the pioneering technologies brought forward by illumiSonics. He brings extensive knowledge in optical system design, hardware implementation, and physical modeling.